Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

3(42.9%)

7Total

Phase 1(4)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02089763Phase 2Completed

Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer

Role: lead

NCT02285101Phase 1Completed

Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors

Role: lead

NCT01551628Phase 1Terminated

A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma

Role: lead

NCT02089633Phase 2Completed

Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC

Role: lead

NCT02899286Phase 2Unknown

Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Role: lead

NCT01092091Phase 1Completed

Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)

Role: lead

NCT00988195Phase 1Completed

Study of Pegylated Human Recombinant Arginase for Liver Cancer

Role: lead

All 7 trials loaded